Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552253 | 0.86 | HTT (0.52) | KDM4ELMNAHTTNPSR1BCHE | |
| SCHEMBL3798888 | 0.83 | KDM4A (0.40) | KDM4ACACNA1HCACNA1BCACNA1CCYP1A2 | |
| SCHEMBL3586130 | 0.83 | KDM4A (0.40) | KDM4ACACNA1HCACNA1BCACNA1CCYP1A2 | |
| SCHEMBL6464868 | 0.82 | KDM4A (0.40) | KDM4ACACNA1HCACNA1BCACNA1CCYP1A2 | |
| SCHEMBL3583656 | 0.82 | KDM4A (0.40) | KDM4ACACNA1HCACNA1BCACNA1CCYP1A2 | |
| SCHEMBL24387623 | 0.81 | MAPKAPK2 (0.42) | KDM4AKDM4ELMNAHTTNPSR1 | |
| SCHEMBL21129147 | 0.79 | HDAC1 (0.39) | KDM4AKDM4ELMNAHTTNPSR1 | |
| SCHEMBL18078935 | 0.78 | KDM4E (0.40) | KDM4AKDM4ELMNAL3MBTL1CA12 | |
| SCHEMBL10315062 | 0.77 | KDM4A (0.39) | KDM4AKDM4ELMNAHTTL3MBTL1 | |
| SCHEMBL3796522 | 0.77 | CA1 (0.39) | KDM4ACACNA1HCACNA1BCACNA1CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-9186402-B2 | Method for preparing largazole analogs and uses thereof | Colorado State University Research University (US) | 2015-11-17 | — | — | US | disclosed |
| US-8513290-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | KDM4A 1717/4885CACNA1H 4590/4885CACNA1B 4403/4885 |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | KDM4A 1717/4885CACNA1H 4590/4885CACNA1B 4403/4885 |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | KDM4A 1717/4885CACNA1H 4590/4885CACNA1B 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.